Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSTANT: Inhaled Flecainide for Paroxysmal Atrial Fibrillation
NCT03539302Phase 2Completed
- Sponsor
- InCarda Therapeutics
- Start
- May 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of flecainide acetate inhalation solution in Atrial fibrillation (AFib), sponsored by InCarda Therapeutics. Started May 2018; status: completed.
02
Drugs
flecainide acetate inhalation solution
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03539302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539302.